Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

被引：0

作者：

Caffo, O. ^{[1
]}

Palesandro, E. ^{[2
]}

Nole, F. ^{[3
]}

Gasparro, D. ^{[4
]}

Mucciarini, C. ^{[5
]}

Aieta, M. ^{[6
]}

Zagonel, V. ^{[7
]}

Iacovelli, R. ^{[8
]}

De Giorgi, U. F. F. ^{[9
]}

Rossetti, S. ^{[10
]}

Fratino, L. ^{[11
]}

Ermacora, P. ^{[12
]}

Nicodemo, M. ^{[13
]}

Giordano, M. ^{[14
]}

Sartori, D. ^{[15
]}

Scapoli, D. ^{[16
]}

Verri, E. ^{[3
]}

Maines, F. ^{[17
]}

Pappagallo, G.

Aglietta, M. ^{[18
]}

机构：

[1] Osped Santa Chiara, Med Oncol, Trento, Italy

[2] IRCCS Candiolo, Dipartimento Oncol Med, Candiolo, Italy

[3] Ist Europeo Oncol, Med Oncol, Milan, Italy

[4] AOU Parma, Med Oncol, Parma, Italy

[5] Osped Ramazzini, Med Oncol, Carpi, Italy

[6] Ctr Riferimento Oncol Basilicata IRCCS, Med Oncol, Rionero In Vulture, Italy

[7] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy

[8] Fdn Policlin Agostino Gemelli, IRCCS, Rome, Italy

[9] Ist Tumori Romagna IRST, Dept Med Oncol, Meldola, Forli Cesena, Italy

[10] Fdn Pascale, Unita Dipartimentale Uroandrol, Naples, Italy

[11] CRO, Med Oncol, Aviano, Italy

[12] AOU Udine, Med Oncol, Udine, Italy

[13] Negrar Canc Ctr, Med Oncol, Negrar, Italy

[14] Presidio Osped Osped St Anna, Med Oncol, San Fermo Battaglia, Italy

[15] Osped Civiile Dolo, Med Oncol, Dolo, Italy

[16] Azienda Osped Ferrara St Anna, Med Oncol, Ferrara, Italy

[17] Osped Santa Chiara, Oncol, Trento, Italy

[18] Ist Candiolo FPO IRCCS, Med Oncol, Candiolo, Italy

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

854P

引用

页码：333 / 333

页数：1

共 50 条

[1] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
Caffo, Orazio
Palesandro, Erica
Nole, Franco
Gasparro, Donatello
Mucciarini, Claudia
Aieta, Michele
Zagonel, Vittorina
Iacovelli, Roberto
De Giorgi, Ugo
Rossetti, Sabrina
Fratino, Lucia
Sacco, Cosimo
Nicodemo, Maurizio
Giordano, Monica
Sartori, Donata
Scapoli, Daniela
Verri, Elena
Kinspergher, Stefania
Pappagallo, Giovanni L.
Aglietta, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[2] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
Caffo, Orazio
Palesandro, Erica
Nole, Franco
Gasparro, Donatello
Mucciarini, Claudia
Aieta, Michele
Iacovelli, Roberto
De Giorgi, Ugo
Rossetti, Sabrina
Maruzzo, Marco
Fratino, Lucia
Sacco, Cosimo
Nicodemo, Maurizio
Giordano, Monica
Sartori, Donata
Scapoli, Daniela
Verri, Elena
Veccia, Antonello
Pappagallo, Giovanni L.
Aglietta, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide Versus Docetaxel as First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer-CHEIRON Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 12 - 12
[4] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
Caffo, Orazio
Ortega, Cinzia
Nole, Franco
Gasparro, Donatello
Mucciarini, Claudia
Aieta, Michele
Zagonel, Vittorina
Iacovelli, Roberto
De Giorgi, Ugo
Facchini, Gaetano
Veccia, Antonello
Palesandro, Erica
Verri, Elena
Buti, Sebastiano
Razzini, Giorgia
Bozza, Giovanni
Maruzzo, Marco
Ciccarese, Chiara
Schepisi, Giuseppe
Rossetti, Sabrina
Maines, Francesca
Kinspergher, Stefania
Fratino, Lucia
Ermacora, Paola
Nicodemo, Maurizio
Giordano, Monica
Sartori, Donata
Scapoli, Daniela
Sabbatini, Roberto
Lo Re, Giovanni
Morelli, Franco
D'Angelo, Alessandro
Vittimberga, Isabella
Lippe, Paolo
Carrozza, Francesco
Messina, Caterina
Galli, Luca
Valcamonico, Francesca
Porta, Camillo
Pappagallo, Giovanni
Aglietta, Massimo
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
[5] Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide plus docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial
Caffo, Orazio
Aieta, Michele
Palesandro, Erica
Macerelli, Marianna
Mucciarini, Claudia
Nicodemo, Maurizio
De Giorgi, Ugo
Sartori, Donata
Fratino, Lucia
Iacovelli, Roberto
Rossetti, Sabrina
Scapoli, Daniela
Morelli, Franco
Carrozza, Francesco
Nole, Franco
Zagonel, Vittorina
Messina, Carlo
Gasparro, Donatello
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[6] A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC).
Caffo, O.
Sava, T.
Comploj, E.
Fariello, A.
Zustovich, F.
Valduga, F.
Frisinghelli, M.
Segati, R.
Sacco, C.
Perin, A.
Pappagallo, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 247S - 247S
[7] Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer
Passildas-Jahanmohan, Judith
Eymard, Jean-Christophe
Pouget, Melanie
Kwiatkowski, Fabrice
Van Praagh, Isabelle
Savareux, Laurent
Atger, Marc
Durando, Xavier
Abrial, Catherine
Richard, Damien
Ginzac Couve, Angeline
Thivat, Emilie
Monange, Brigitte
Chollet, Philippe
Mahammedi, Hakim
CANCER MEDICINE, 2021, 10 (07): : 2332 - 2340
[8] Randomized phase II study of docetaxel (D) plus abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial
Climent Duran, Miguel Angel
Font, Albert
Duran, Ignacio
Puente, Javier
Castellano, Daniel
Isabel Saez, M.
Mendez Vidal, Maria Jose Jose
Santander, Carmen
Arranz Arija, Jose Angel
Gonzalez del Alba, Aranzazu
Sanchez-Hernandez, Alfredo
Esteban, Emilio
Alonso Gordoa, Teresa
Maroto, Pablo
Lazaro Quintela, Martin Emilio
Cassinello, Javier
Perez Valderrama, Begona
Juan Fita, Maria Jose
Mellado, Begona
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[9] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Huang, X.
Ning, Y. M.
Mulquin, M.
Madan, R. A.
Gulley, J. L.
Kluetz, P. G.
Adelberg, D.
Arlen, P. M.
Parnes, H. L.
Adesunloye, B.
Steinberg, S. M.
Wright, J. J.
Trepel, J. B.
Chen, C.
Bassim, C.
Apolo, A. B.
Figg, W. D.
Dahut, W. L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC)
Huang, X.
Ning, Y. M.
Gulley, J. L.
Kluetz, P. G.
Adelberg, D.
Mulquin, M.
Madan, R. A.
Bassim, C.
Figg, W. D.
Dahut, W. L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)

← 1 2 3 4 5 →